English | 简体中文 | 繁體中文 | 한국어
Share:
Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017

PRESS RELEASE

Lund - Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB. Helén Tuvesson will take up the position on July 1, 2017, replacing Tomas Leanderson, who has been the company's CEO since 2008.

Helén Tuvesson has a broad experience in drug development after more than 20 years in the pharmaceutical industry. Helén has held various senior positions in Active Biotech and since 2011 she has been responsible for the company's research and development.

"I am proud and glad that in Helén Tuvesson we have an internal candidate who can take responsibility as CEO, ensuring continuity and a controlled handover. Helén has been instrumental in the structural changes made in the company during 2016/2017 and has a solid industry experience. I am convinced that she has the qualities required to shape the company's future strategy and maximize its opportunities," says Mats Arnhög, Chairman of the Board.

"I would also like to thank Tomas Leanderson for his significant contribution to the company's business for a long period. Tomas Leanderson will be at the company's disposal during a transitional period," said Mats Arnhög.

"I am very happy and at the same time humbled for the confidence to lead Active Biotech further. I am well acquainted with the company's projects and its potential and look forward to developing the portfolio further and creating value for the company," says Helén Tuvesson.

Lund June 19, 2017
Active Biotech AB (publ)

For further information, please contact:
Mats Arnhög
Chairman of the Board
Tel +46 8 54503770
Mobil: +46 705 915096

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 15.30 a.m. CET on June 19, 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Copyright © Thomson Reuters 2017. All rights reserved.
 Subscribe RSS Feed  
Press Releases
Nordic American Tankers Limited (NYSE:NAT) - Renewal and Filing of Shelf Registration Statement  
June 23, 2017 18:58 ET
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)  
June 23, 2017 18:00 ET
Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial  
June 23, 2017 16:45 ET
Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial  
June 23, 2017 13:40 ET
Medtronic Announces 7 Percent Increase in Cash Dividend  
June 23, 2017 12:45 ET
Sequa Petroleum N.V. Funding Update  
June 21, 2017 00:03 ET
AIR Worldwide Releases Updated Earthquake Model for the United States  
June 19, 2017 18:13 ET
Schrader Cellars Entrusts Constellation Brands with Highly-Coveted, Critically-Acclaimed Wine Portfolio  
June 17, 2017 04:33 ET
Kymab Group Ltd: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair  
June 16, 2017 16:03 ET
NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop  
June 16, 2017 03:53 ET
More News >>
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: